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1. Introduction 
 
1.1. Hepatocellular carcinoma (HCC) 
 
1.1.1 Prevalence and Incidence 
 
Hepatocellular carcinoma (HCC) is the predominant primary liver cancer. It is the fifth 
most common cancer and third most common cause of death from cancer worldwide 
(Mittal et al., 2013). The annual incidence is estimated to exceed 750,000 cases 
worldwide (Ferlay et al., 2011). HCC is more frequent in males than in females with 
ratios averaging between 2:1 and 4:1 (El-Serag et al., 2007). The majority of HCC cases 
(> 80%) occur in either sub-Saharan Africa or in Eastern Asia. China accounts for more 
than half of the world’s cases (Parkin DM, 2002).  
 
 
1.1.2 Epidemiology and risk factors  
 
The majority of patients (70 - 90%) developing HCC have a background of chronic 
liver disease (Sherman, 2010). In fact, any agent that eventually leads to chronic liver 
injury or cirrhosis is an oncogenic agent for HCC (Bruix et al., 2004). The geographical 
variation of HCC is owed to the heterogeneity of risk factor penetration within the 
population (Llovet et al., 2003). For instance, in Eastern Asia and sub-Saharan Africa, 
the dominant risk factor is chronic infection with hepatitis B virus (HBV) as well as 
exposure to aflatoxin B1 whereas in North America, Europe and Japan, infection with 
hepatitis C virus (HCV) represents the main risk factor together with alcohol intake (El 
Serag, 2011). A recent study by our group demonstrated that in Southern Germany, the 
most common risk factor was chronic alcohol abuse with 57.2%, followed by HBV and 
HCV infections with 19.9% and 20.5%, respectively (Kirchner et al, 2010). However, 5 
– 30% of patients with HCC lack a readily identifiable risk factor for liver cancer. 
Today, it is believed that the majority of these HCC cases are attributed to non-alcoholic 
fatty liver disease (NAFLD) (Sun et al., 2012). It starts with hepatocellular lipid 
accumulation, i.e. steatosis, and can progress with inflammation to non-alcoholic 
steatohepatitis (NASH), which often develops in obese people. (Hellerbrand 2010; Sun 
et al., 2012). More precisely, NAFLD is a hepatic manifestation of the metabolic 
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syndrome (Adams et al., 2007; Farrell et al., 2006). In fact, obesity and its consequences 
make a larger contribution to overall HCC burden than HBV and HCV infections. The 
reason for this is that obesity is spread wider and its prevalence is higher in some parts 
of the world (Sun et al., 2012). Additionally, diabetes has been proposed to be an 
independent risk factor for both chronic liver disease and HCC through the development 
of NAFLD and NASH (El-Serag and Rudolph, 2007). 
 
 
 
1.1.3 Carcinogenesis 
 
Hepatocarcinogenesis is a complex process that is associated with accumulation of 
genetic and epigenetic alterations that occur during initiation, promotion and 
progression of the disease. Certain mechanisms that have been revealed for cancer 
pathogenesis in general, can as well be applied for HCC. For instance, cellular events 
are often accompanied by increase of expression of several factors that influence the 
survival of cancerous cells by inhibiting apoptosis and regulating cell cycle. In 
particular, oncogenes and tumor suppressor genes have turned out to play a key role 
(Aravalli et al., 2008). Different concepts of hepatocarcinogenesis have been developed: 
multistep carcinogenesis, cell proliferation coupled with aberrations in tumor suppressor 
genes and inhibition of apoptosis, and finally the cancer stem cell concept (Cha and 
Dematteo, 2005). A general observation is that carcinogenesis is tightly linked to 
chronic liver damage, as HCC rarely develops in healthy liver during normal aging. A 
possible explanation for this correlation might be that cancer development in liver tissue 
requires cell division because genetic hits are acquired step-wisely which are necessary 
for cellular transformation (El-Serag and Rudolph, 2007). In particular the persistent 
liver injury, inflammation and compensatory hepatocyte proliferation are characteristics 
of cirrhosis and chronic hepatitis (Szabo and Lippai, 2012). Although it is known that 
there is a sequence of development from NASH and cirrhosis to HCC, the exact 
molecular basis still needs to be deciphered (Siegel et al., 2009).   
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1.1.4 Therapy and Prognosis 
 
Although new strategies for HCC therapy have evolved perpetually, it still remains a 
highly aggressive form of cancer with poor prognosis due to frequently late diagnosis. 
Its prognosis is dismal with a 5-year survival of 11%. A widely used prognostic 
indicator in patients with cirrhosis is Child score or Child-Pugh score, a slightly 
modified form published ten years later. It includes five variables (albumin, bilirubin, 
presence of ascites, encephalopathy and prothrombin time), which define the degree of 
severity (A, B and C as the subgroup with worst prognosis) by the aid of a score system 
(Child and Turcotte, 1964; Pugh et al., 1973). Higher Child scores correlate negatively 
with prognosis (Kirchner et al., 2010). Only surgical resection or orthotopic liver 
transplantation turned out to be potentially curative (Blechacz and Mishra, 2013). 
Nevertheless, percutaneous radiofrequency ablation (RFA) is a validated curative 
therapy for early-stage tumours (Fares and Péron, 2013). In patients without cirrhosis, 
the best treatment is hepatic resection as they can recover from resection preserving a 
minimum of two liver segments that are functional (Song et al., 2004). However, in 
patients suffering from cirrhosis, only those with well-preserved cirrhosis and those 
who could tolerate resection of up to two segments could be proposed surgery. Main 
prognostic factors after resection are presence of cirrhosis, tumor size, vascular invasion 
and poorly differentiated HCC. Unfortunately, often only poor prognosis is to be 
expected due to high rates of postoperative recurrences (Raoul, 2008). However, 
transarterial chemoembolisation (TACE) and the chemotherapeutic agent sorafenib can 
improve survival for patients with intermediate and advanced tumors, respectively 
(Bruix et al., 2011). Especially sorafenib, which is a multi-kinase inhibitor, offers the 
first effective treatment for progressed HCC (Llovet et al., 2008). Superior to all 
mentioned therapeutical opportunities is liver transplantation, which seems to be the 
ultimate cure for HCC. Advantageously, both the tumor and the underlying cirrhosis are 
eliminated by transplantation at the same time (Mazzaferro et al., 1996; Yao et al., 
2002). For patients with a tumor burden exceeding conventional criteria however, 
dismal prospects are to be observed due to high tumor recurrence (Klintmalm, 1998; 
Shirabe et al., 2011). Nevertheless these patients still have a significant chance of cure 
following liver transplantation, which has led to proposal of several downstaging 
therapies that are as well applied in conventional therapy (Lei et al., 2013). For instance, 
downstaging options are transarterial chemoembolization (TACE), RFA, liver resection, 
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transarterial chemoinfusion and sorafenib, respectively (Ravaioli et al., 2008; de Luna et 
al., 2009). To sum up, current therapeutical strategies in HCC are rather unsatisfying. 
Recent studies however provide significant insights into hepatocarcinogenesis and 
signalling cascades which might give new impulses for the development of molecular 
targeted therapies (Blechacz and Mishra, 2013).  
 
 
1.2 Metabolic Syndrome 
 
1.2.1 Definition  
 
Patients combining various metabolic abnormalities already were described in 1923 
(Parikh and Mohan, 2012). However, it was more than five decades later that the 
constellation of the coexisting factors insulin resistance, hyperglycaemia, hypertension, 
low HDL-cholesterol and raised VLDL-triglycerides was first mentioned in scientific 
publications by Reaven in 1988, terming this cluster “syndrome X” (Reaven G, 1988). 
A variety of possible names were proposed in the following, whereas “metabolic 
syndrome” eventually made the race to be the most popular term in nomenclature today. 
Remarkably, Reaven’s definition did not include obesity or in particular, visceral 
obesity, which nowadays is considered as one of the main features (Eckel et al., 2005; 
Alberti et al., 2005). A recent study exemplarily showed for China, one of the fastest 
developing countries in the world, that increased urban migration, the adoption of 
sedentary lifestyles and especially increasing prosperity causes increasing rates of 
affliction with typical wealth diseases. The rates of the metabolic syndrome are already 
approaching those usually found in industrialized countries in both Europe and the USA 
(Shen et al., 2012). Today, there is still confusion about the definition of the metabolic 
syndrome. The first suggestion of a suitable definition was attempted by the WHO in 
1999 (Fig. 1.1). However, it was stated clearly that it has to be improved in due course 
of time (Alberti and Zimmet, 1998). Several other definitions, such as the one by the 
National Cholesterol Education Program’s Adult Treatment Panel III (NCEP: ATP III) 
followed. Retrospectively, the WHO definition is more suitable for research whereas the 
NCEP: ATP III definition seems to be more useful for clinical practice (Eckel et al., 
2005).   
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WHO (1999) 
 
Diabetes, impaired fasting glucose, impaired 
glucose tolerance OR insulin resistance 
PLUS at least two of the following: 
 
o Obesity: BMI > 30 or waist-to-hip ratio > 0.9 
(male) / 0.85 (female) 
o Dyslipidemia: triglycerides > 1.7 mmol/l OR 
HDL cholesterol < 0.9 (male) / < 1.0 (female) 
mmol/l 
o Hypertension: blood pressure > 140/90 
mmHg 
o Microalbuminuria: albumin excretion > 
20µg/min 
 
CEP: ATP III (2001) 
 
AY three or more of the following: 
 
 
 
o Obesity: waist circumference > 102 cm 
(male) / > 88 cm (female) 
o Hypertriglyceridemia: triglycerides > 1.7 
mmol/l 
o low HDL cholesterol: < 1.0 mmol/l(male)/ < 
1.3 mmol/l (female) 
o Hypertension: blood pressure > 135/85 
mmHg or medication 
o Fasting plasma glucose > 6.1 mmol/l 
 
Figure 1.1 Comparison of the definitions of the metabolic syndrome. The WHO definition is more 
suitable for research trials, the NCEP: ATP III definition on the other hand more feasible for clinical 
practice. Both definitions highlight the relevance of obesity and high blood levels of triglycerides as well 
as hypertension.   
 
Certain factors such as obesity, dyslipidemia and high plasma glucose levels appear in 
both definitions. To sum up, the metabolic syndrome is a multifaceted problem, which 
pieces together various metabolic abnormalities (Siegel et al., 2009).   
 
 
1.2.2 Pathogenesis 
 
As the metabolic syndrome summarizes various metabolic abnormalities with 
interrelationship, there is not one particular trigger, but a variety of pathways ending up 
to this pathologic metabolic status. There are various further complications associated 
with it (Eckel et al., 2005). The list of factors contributing to the development of the 
metabolic syndrome is long: lifestyle characteristics such as diet and lack of physical 
activity, obesity, genetic predisposition, chronic inflammation and the presence of 
cytokines, adipokines, elevated blood levels of free fatty acids (FFA), mitochondrial 
dysfunction and alterations in insulin signalling pathways (Gallagher et al., 2010). A 
distressing fact is that the incidence in both children and adults has increased drastically 
in the past three decades not only in Europe and Northern America, but also in 
developing countries such as China and India (Flegal et al., 2000; Hedley et al., 2004; 
Ogden et al., 2002). The pathophysiology of the metabolic syndrome is a complex 
process (Gallagher et al., 2010), as it encompasses several interacting factors. Yet, the 
most accepted and unifying pathophysiological hypothesis is insulin resistance (Eckel et 
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al., 2005). The mechanism of its development is linked tightly to an increased level of 
FFA, which is a typical finding in obese individuals (Gallagher et al., 2010). 
Simultaneously, insulin levels are elevated, which is thought to be due to an increase in 
lipolysis because of the activity of hormone-sensitive lipase (HSL). This enzyme 
normally is inhibited by insulin. A further increase of FFA impairs insulin signalling, 
which consequently leads to even higher levels of FFA ending up in a vicious circle 
(Guilherme et al., 2008). Surprisingly, this condition of insulin resistance is reversible 
to a certain degree, as in individuals with obesity and Type 2 diabetes mellitus insulin 
sensitivity improves, when FFA levels are lowered (Santomauro, 1999). A concrete 
example for the effects of elevated levels of FFA is their contribution to the 
development of NAFLD in insulin-resistant individuals, which adversely affects insulin 
sensitivity in other tissues (Hwang et al., 2007). Metabolically, the insulin resistance 
and the elevated levels of FFA result in various changes: production of proinflammatory 
cytokines, mitochondrial dysfunction, and abnormal levels of adipokines. Taken as a 
whole, these features contribute to the development of hypertension, dyslipidemia and 
hyperglycemia, forming the main aspects of the metabolic syndrome (Gallagher et al., 
2010). An increased risk for cardiovascular disease and type 2 diabetes mellitus is 
associated with the metabolic syndrome in the long term (Hunt et al., 2004). To sum up, 
several steps of pathogenesis have already been revealed in various studies. However, it 
rests a confusing and challenging topic, as the individual factors mutually are 
aggravating. Naturally, this conjures up the question: What is chicken, what is egg? 
 
 
1.2.3 Therapeutical options and clinical management 
 
Insulin resistance plays a key role in the pathophysiology of the metabolic syndrome 
(see chapters 1.2.1; 1.2.2). Therefore, any therapeutic manoeuvre that improves insulin 
sensitivity will have a beneficial effect on the metabolic abnormalities linked to it. 
However, some dietary factors are know to have no influence on insulin sensitivity but 
nevertheless are able to modify one or more features of the metabolic syndrome. 
Therefore individualized dietary recommendations are necessary and individual 
abnormalities that are present at the patient need to be taken into consideration (Riccardi 
and Rivellese, 2000). The great majority of patients are overweight and therefore 
primarily should put their focus on weight reduction by adequate diet and regular 
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exercise. Further suggestions are to maintain a diet with reduced intakes of saturated 
fats and cholesterol, complete smoking cessation, LDL-cholesterol lowering drugs at 
high risk patients, antihypertensive drugs when necessary, hypoglycemic agents for 
patients who do not achieve an adequate glucose level or whose HbA1c levels are 
elevated. At patients with prothrombotic states, a low-dose aspirin or clopidogrel 
therapy should be initiated (Eckel et al., 2005).  
 
 
 
1.3 Metabolic syndrome and HCC – where is the link? 
 
The difference to most other liver diseases is that NAFLD occurs in the context of a 
systemic disease, which is highlighted by diabetes mellitus and insulin resistance 
(Bosserhoff and Hellerbrand, 2011). More precisely, NAFLD itself is not only 
considered to be a component of the metabolic syndrome but even the driving force for 
insulin resistance (Hellerbrand 2010). Various case reports, case series and studies have 
reported the association between metabolic syndrome, NAFLD or NASH and 
hepatocellular carcinoma (HCC) (Starley et al., 2010; Adams et al., 2005; Siegel et al., 
2009). As previously described, the metabolic syndrome comprises numerous metabolic 
abnormalities and problems. An important factor that reduces both metabolic syndrome 
and HCC to a common denominator is obesity. A frequent comorbidity in obese 
individuals is diabetes mellitus, which therefore needs to be elucidated, as well.  
 
 
1.3.1 Obesity and HCC 
 
Obese individuals frequently suffer from insulin resistance. The mechanism of 
cancerogenesis in individuals with metabolic syndrome is frequently associated with 
insulin resistance as a key point. One assumes that defects in the signalling pathways of 
insulin lead to insulin resistance which in turn contributes to hepatic fat accumulation 
(see chapter 1.2.2) by lipolysis (Angulo et al., 2002). The level of free fatty acids is 
elevated in the plasma of patients with metabolic syndrome and the resulting hepatic 
steatosis (Bullock et al., 2004). Their excess is responsible for hepatic inflammation 
through the production of cytokines like TNF-α. In the following, the “second hit” 
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might be conducted by dysfunctional mitochondria producing free radicals and 
oxidative stress (Bullock et al., 2004). In particular, the process of mitochondrial fatty 
acid oxidation is inhibited by insulin resistance. The emerging intracellular free fatty 
acid (FFA) accumulation leads to oxidative DNA damage due to stimulated microsomal 
peroxidases (Bullock et al., 2004). This whole process causes progression from simple 
steatosis to steatohepatitis and is an important initial step in the development of HCC 
(Angulo, 2002; Luedde et al., 2007). Notably, cirrhosis is not an obligatory intermediate 
step on the way to HCC (Bullock et al. 2004). Another association has been drawn with 
regards to plasma levels of leptin, which are found to be elevated in patients with 
NASH and also in obese individuals pointing to a possible role for increased 
angiogenesis and vascular invasiveness in HCC in the setting of the metabolic 
syndrome (Chitturi et al., 2002).  
 
 
1.3.2 Diabetes Mellitus and HCC 
 
Additionally to lipids, the quantity and quality of carbohydrates was shown to have a 
major impact on hepatic steatosis, inflammation and fibrosis in experimental models 
(Hellerbrand 2010, Bergheim 2008, Feldstein 2003). Diabetes mellitus is a known risk 
factor for both chronic liver disease and HCC through the development of NAFLD and 
NASH.  Several case-control studies revealed a significant positive association between 
diabetes and HCC. Approximately 10-20% of patients with cirrhosis have overt diabetes 
and an even higher percentage have impaired glucose tolerance. Nevertheless, it is 
believed that peripheral insulin resistance is “primary” and leads to hepatic steatosis, 
which in turn can contribute to peripheral and hepatic insulin resistance (Smedile and 
Bugianesi; 2005). Recent data suggests that diabetes is likely to be associated with a 2-
fold to 4-fold increased risk of HCC (Adami et al., 1996; El-Serag et al., 2004). Of 
course, the previous described mechanism of cancerogenesis for insulin resistance in 
obese people exists in patients suffering exclusively from diabetes, too. As obesity and 
type 2 diabetes mellitus are comorbidities, the bridge is built to obesity and thus to the 
metabolic syndrome, again.  
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1.4 Aim of the thesis  
 
Aggregating the complex confounding risk factors and etiologic mechanism of 
hepatocarcinogenesis, it becomes clear that a change in lipid metabolism plays a key 
role. Currently, it remains rather unclear whether diabetes, obesity and the metabolic 
syndrome are risk factors for HCC independent of NAFLD. However, it is likely that 
NAFLD usually mediates the relation between the metabolic syndrome and HCC, 
which is based on the high correlation between features of metabolic syndrome and 
NAFLD (Siegel et al., 2009). Thus, carcinogenesis may relate at least in parts to the 
intermediate steps of changes related to fatty acids in the liver and insulin resistance 
(Siegel et al., 2009). Naturally, it is mandatory to take a closer look at those individuals 
having already developed a HCC against the background of the metabolic syndrome. 
Considering the different interacting phenomenona of the metabolic syndrome 
occurring during carcinogenesis, one might speculate that elevated FFA levels play a 
key role for tumor progression and metastasis, as well. Therefore, the aim of this thesis 
was to assess the effects of FFA and cellular lipid accumulation, respectively, on 
proliferation and migration of HCC cells in vitro.  
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2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 Chemicals and reagents 
 
β-Mercaptoethanol    Sigma-Aldrich, Deisenhofen, Germany 
DMEM medium   PAA Laboratories, Cölbe, Germany 
FCS (fetal calf serum)  PAN-Biotech, Aidenbach, Germany 
Penicillin    Invitrogen, Karlsruhe, Germany 
Streptomycin    Invitrogen, Karlsruhe, Germany 
Trypsin/EDTA   PAA Laboratories, Cölbe, Germany 
 
 
2.1.2 Laboratory expendables  
 
CryoTube vials   Nunc, Roskilde, Denmark 
Pipet tips     Eppendorf, Hamburg, Germany 
(10, 20, 100 and 1000 µl)   
Falcon tubes (50 ml)   Corning, New York, Germany 
glassware (various)   Schott, Mainz, Germany  
Multiwell plates   Corning, New York, USA 
Pipettes (stripettes ®)   Corning, New York, USA 
(5, 10, 25, 50 ml)   
Reaction vessels (1.5 and 2 ml) Eppendorf, Hamburg, Germany 
Cell culture flasks T25, T75, T175 Corning, New York, USA 
 
 
2.1.3 Laboratory instruments 
 
Heating block: 
Thermomixer comfort  Eppendorf, Hamburg, Germany 
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Pipettes: 
Eppendorf Research 
(1000, 200, 100, 20, 10 and 2 µl) Eppendorf, Hamburg, Germany 
Pipette controllers: 
Accu-jet ®    Brand, Wertheim, Germany 
Shaking device: 
KS 260 Basic Orbital Shaker  IKA® Werke, Staufen, Germany 
Spectrophotometer: 
EMax® Microplate Reader  MWG Biotech, Ebersberg, Germany 
SPECTRAFluor Plus   Tecan Männedorf, Switzerland 
Scales: 
MC1 Laboratory LC 620 D  Sartorius, Göttingen, Germany 
Water bath: 
Haake W13/C10   Thermo Fisher Scientific, Karlsruhe, Germany 
xCELLigence system: 
Real-Time Cell Analyser (RTCA) Roche Diagnostics, Mannheim, Germany  
Centrifuges: 
Biofuge fresco   Heraeus, Hanau, Germany 
Megafuge 1.0 R   Heraeus, Hanau, Germany 
Microscope: 
Olympus CKX41 with  Olympus Hamburg, Germany 
ALTRA20 soft imaging system  
 
 
2.1.4 Buffer  
 
PBS buffer    140 mM NaCl 
     10 mM KCl 
     6.4 mM Na2HPO4  
     2 mM  KH2PO4  pH 7.4 
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2.2 Methods 
 
2.2.1 Cell culture 
 
2.2.1.1 Cell culture medium  
DMEM (high glucose/10% FCS) 4.5 g/l   Glucose 
     300 µg/ml  L-Glutamine 
     supplemented with: 
     10% (v/v)  FCS 
     400 U/ml   Penicillin 
     50 µg/ml  Streptomycin 
 
DMEM (low glucose/10% FCS) 1.0 g/l   Glucose 
     300 µg/ml  L-Glutamine 
supplemented with: 
     10% (v/v)  FCS 
     400 U/ml  Penicillin 
     50 µg/ml  Streptomycin 
 
 
2.2.1.2 Cultivation of HCC cells 
Cell culture work was performed within a laminar flow bio safety cabinet (Hera Safe, 
Heraeus, Osterode, Germany) in order to avoid contaminations. The cells were 
cultivated in a Binder series CB incubator (Binder, Tuttlingen, Germany) in 10% CO2 
atmosphere at 37°C. As cell culture medium DMEM containing 4.5 g/l glucose and 
300µg/ml L-Glutamine supplemented with 10% (v/v) FCS, 400 U/l penicillin and 50 
µg/ml streptomycin was used. For cell passaging cells first were washed with PBS and 
then detached with trypsin (0.05%)/ EDTA (0.02%) (PAA Laboratories, Cölbe, 
Germany) at 37°C.  The same volume of DMEM was used to stop trypsin activity. 
Subsequently, the obtained cell suspension was transferred into a falcon tube and then 
centrifuged at 500 g for 5 min. The obtained cell pellet was resuspended in fresh culture 
medium and cell number was determined (see chapter 2.2.1.3). A cell density thinning 
factor of 5 to 10 was used when cells were distributed to new cell culture flasks. 
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Medium change took place every second day. Cell growth and morphology were 
monitored and documented using a microscope (Olympus CKX41 with ALTRA20 Soft 
Imaging System, Olympus, Hamburg, Germany). Accrued cell culture waste was 
autoclaved before disposal with Sanoclav autoclave (Wolf, Geislingen, Germany).  
 
2.2.1.3 Determination of cell number and viability 
To determine cell number and viability, cells were diluted 1:2 with trypan blue solution 
(Sigma, Deisenhofen, Germany) and applied on a Neubauer hemocytometer 
(Marienfeld GmbH, Lauda-Königshofen, Germany).  The test is based on the principle 
that live cells with intact cell membranes have a clear cytoplasm whereas nonviable 
cells are stained blue. Therefore, intact cells can easily be distinguished under 
microscopic inspection. To determine total cell number, cells were counted in all four 
quadrants of the hemocytometer (each containing sixteen smaller squares) and 
calculated with the following equation: 
 
 Cell number/ml = Z x DF x 104 ÷ 4  
 Z : counted cell number in all four quadrants 
 DF : dilution factor (in the described procedure the factor is 2) 
 
The ratio of viable cells could be determined by setting the number of unstained cells in 
relation to the total cell number (blue and unstained cells). 
 
2.2.1.4 Human hepatocellular carcinoma cell lines 
Hep G2    ATCC HB-8065 
Hep 3B    ATCC HB-8064 
HUH7     JCR B0403 
PLC     ATCC CRL-8024 
The hepatocellular carcinoma cell lines were obtained from the American Type Culture 
Collection (ATCC).  
 
2.2.1.5 Free fatty acids – quantification assay 
For the quantification of free fatty acids in cell pellets, the Free Fatty Acids, Half Micro 
Test assay from Roche (Roche Diagnostics, Mannheim, Germany) was used. 
Metabolically, FFAs are converted into acyl-CoA by ATP and CoA in a reaction 
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catalyzed by Acyl CS, yielding AMP and pyrophosphate. Acyl-CoA reacts with oxygen 
in the presence of acyl-CoA oxidase (ACOD) to form 2,3-enoyl-coenzyme A (enoyl-
CoA). The resulting hydrogen peroxide (H2O2) converts 2,4,6-tribromo-3-hydroxy-
benzoic acid (TBHB) and 4-aminoantipyrine (4-AA) to a red dye in the presence of 
peroxidase (POD).The dye is measured at a wavelength of 540 nm. For this assay, cells 
were seeded in 6-well plates (Corning, New York, USA) in an adequate density and 
grown overnight. This was followed by stimulation with different oleate concentrations 
for 48 hours. Cells were washed with PBS buffer and harvested.  After trypsinizing and 
centrifugation, culture supernatant was removed. This was followed by washing with 
PBS two times and centrifugation until a dry cell pellet was obtained by removing 
supernatant. Cell pellets of all four investigated cell types of HCC were examined after 
48h of stimulation with defined concentrations of oleate. A standard solution has 
previously been prepared according to the instructions in the protocol to generate a 
standard curve and to ensure accurate measurement. Therefore, Triton® X-100 was 
dissolved in distilled water and allowed to cool to 15 °C. This solution was combined 
with a second one, containing palmitic acid, having been dissolved in warm ethanol. 
Next, the kit itself was prepared by combining the solutions 1-5 to make reaction 
mixtures A and B. The assay was performed according to the manufacturer’s 
instructions. 
 
2.2.1.6 Triglycerides – quantification assay  
The quantitative determination of triglycerides in cell pellets was analysed with 
Triglyceride GPO-PAP assay from Roche (Roche Diagnostics, Mannheim, Germany). 
Triglycerides are synthesized in the liver and ingested in food, respectively. The 
determination of triglycerides is utilized in the diagnosis and treatment of patients 
having diabetes mellitus, nephrosis, liver obstruction, lipid metabolism disorders and 
numerous other diseases such as steatosis. This method of enzymatic determination of 
triglycerides is using a lipoprotein lipase from microorganisms for the rapid and 
complete hydrolysis of triglycerides to glycerol followed by oxidation to 
dihydroxyacetone phosphate and hydrogen peroxide. The hydrogen peroxide then reacts 
with 4-aminophenazone and 4-chlorophenol under the catalytic action of peroxidase to 
form a red dyestuff (Trinder endpoint reaction). The colour intensity of the red dyestuff 
formed is directly proportional to the triglyceride concentration in the investigated 
sample and can be measured photometrically at a wavelength of 540 nm. To determine 
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the intracellular accumulation of triglycerides in HCC, cells were seeded in an 
appropriate density in 6-well plates (Corning, New York, USA) and grown overnight. 
Thereafter, cells were stimulated with different concentrations of oleate for 48 h and 
cell pellets were obtained according to the procedure described in chapter 2.2.1.5 (Free 
fatty acids – assay). A volume of 2 µl of each sample was analyzed according to the 
manufacturer’s instructions.   
 
2.2.1.7 Oil Red O Staining   
Cells perpetually were stimulated with a range of different oleate concentrations in this 
study. Therefore, the aim was not only to show lipid accumulation by cellular analysis 
(see chapters 2.2.1.5, 2.2.1.6), but also to visualize this phenomenon. Oil Red O 
Staining is an adequate method to stain triglycerides and lipids in cells. Compared to 
alcohol fixation, which removes most lipids, Oil Red O is a non-destructive technique 
that has to be performed on fresh samples. Cells were seeded in a 6-well and stimulated 
according to the procedures described in previous chapters (see chapters 2.2.1.5 and 
2.2.1.6). Medium was removed gently from each well using a pipette and wells 
subsequently were rinsed twice with 1 ml of PBS. Fixing was achieved by removing all 
the PBS and adding 1.0 ml of Formalin 10%. Thereafter, the wells were incubated 5 
minutes at room temperature and rinsed with 60% isopropanol followed by drying at 
room air. For Oil Red O Staining, a stock solution was prepared by dissolving 175 mg 
Oil Red O in 50 ml isopropanol, stirring overnight and filtering the solution. The 
working solution consisting of 6 ml stock solution and 4 ml H2Obidest was mixed and 
filtered subsequently. A volume of 2 ml was added to each dried well. The dye solution 
was removed after approximately 40 minutes of incubation. In order to clear fixed cells 
from surplus dye solution, wells were washed four times with H2Obidest. Subsequently, 
wells were evaluated microscopically and photographed.  
 
 
2.2.2 Cell-based functional assays 
 
2.2.2.1 XTT - proliferation assay  
To quantify cell proliferation, the colorimetric XTT kit (Roche Diagnostics, Mannheim, 
Germany) was used. This assay bases upon the ability of metabolic active cells to 
reduce the tetrazolium salt XTT (2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-
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[(phenylamino)carbonyl]-2H-tetrazolium hydroxide) to orange coloured formazan by 
metabolic active cells. Formazan is released into the supernatant. The dye is water 
soluble and therefore intensity can be read directly with a spectrophotometer at a 
wavelength of 450 nm and a reference absorbance wavelength of 650 nm. The intensity 
of the dye directly correlates with the number of metabolically active cells. To quantify 
the effects of FFA on cell proliferation, cells (4 x 103 cells per well) were seeded in 96-
well tissue culture plates (Corning, New York, USA). A proper attachment of cells was 
made sure by having grown cells for approximately 24 hours, before adding stimulants. 
At chosen time points the colorimetric XTT assay (Roche Diagnostics, Mannheim, 
Germany) was used according to the manufacturer’s instructions. The intensity of the 
forming dye was measured one, two and three hours after adding XTT reagent with an 
EMax Microplate Reader (MWG Biotech, Ebersberg, Germany). Figure 2.1 shows the 
difference of measurements after one hour and three hours. The optical density (OD) is 
significantly elevated after three hours, however the relation of elevation remains 
constant. Values of OD at individual time points were corrected for background by 
subtracting the OD value of blank wells without cells. Each experimental condition was 
performed in triplicate and experiments were repeated three times.  
 
Figure 2.1 Proliferation of Hep G2 cells as a function of time of measurement. Values were generated 
for oleate and BSA as stimulants. ol oleate. Values are displayed as mean ± SEM; * p < 0.05 (3h 
compared to 1h) 
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2.2.2.2 xCELLigence System 
The xCELLigence System from Roche (Penzberg, Germany) allows examining both 
attachment and proliferation of cells by the use of so-called E-Plates. With the aid of 
interdigitated micro-electrodes integrated on the bottom of tissue culture E-Plates, 
xCELLigence measures electrical impedance. This value correlates with the number of 
cells and thus can be used as a marker of proliferation and is transmitted in real time as 
a change in cell index to the connected laptop. E-Plates were coated at the beginning of 
the experiment with 100 µl transparent DMEM (without phenol red) with FCS and 
equilibrated for 30 minutes at room temperature. 2 x 103 cells/100 µl DMEM with FCS 
were added after the measurement of background resistance. The E-Plate was inserted 
into the analyzer after incubating the plate for 10 minutes at room temperature. As 
previously described for XTT-assay in chapter 2.2.2.1, cells were grown for 24 hours 
for attachment. Measurement then was paused for adding stimulants and then restarted 
again. The obtained data was evaluated with RTCA software. In this setting, 
xCELLigence system exclusively was used for the purpose of detecting the proliferation 
of HCC cells. The purpose therefore was not only to have an additional approach to 
measure proliferation apart from XTT-assay but also to compare those two methods. 
The advantage of xCELLigence system is that the number of generated test values is not 
limited, as measurements can be observed online. Thus, tiny intervals between 
measurements were possible and consequentially a more specific surveillance of 
proliferation. Experimental trials were conducted with all four HCC cell lines. T-Test 
was used at measure points corresponding to those of XTT-assay (see chapter 3.3.2). 
Measurement with xCELLigence started when plates with seeded cells were put into the 
reading device in the incubator and then grown for approximately 24 hours. With this 
difference to XTT-assay, where the first measurement takes place after adding FFA to 
cells, time points have to be regarded carefully for comparison, here. For instance, 0.0 
days in XTT-assay (see Figures in chapters 3.3.1, 3.3.2), that is to say the time point, 
when stimulants were added, corresponds to the time point “22 hours” for  Hep G2 in 
Figure 3.11. 
 
2.2.2.3 Migration assay 
The Cultrex 96 Well Cell Migration Assay (Trevigen, Gaithersburg, USA) was used to 
quantify the migratory potential of HCC cells. The assay was performed according to 
the manufacturer’s instructions. In general, this assay is based on a plate consisting of 
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two compartments being separated by a microporous membrane. Cells are seeded in the 
upper compartment and the membrane allows them to migrate through the pores to the 
lower compartment, where chemotactic agents are present. After an appropriate 
incubation time, migrated cells were detached carefully from the lower side of the 
membrane using a detachment buffer and quantified calcein acetoxymethylester (calcein 
AM). Calcein AM is absorbed by the cells, and intracellular esterases cleave the 
acetoxymethylester moiety to generate free calcein, which can be detected 
fluorometrically. Cells were seeded into the upper compartment of the provided 96-well 
plate with a density of 4 x 104 cells/ well in DMEM. The distinction between random 
and directional migration was made by adding medium with 20% FCS or 0% FCS, 
respectively, to the lower compartment (see chapter 3.4.1). After incubation at 37 °C for 
5 hours, cell migration was quantified by fluorimetry using a SPECTRAFluor Plus 
microplate reader (Tecan, Männedorf, Switzerland). Each experimental condition was 
performed in triplicates and experiments were repeated three times, at least. 
 
 
2.2.3 Analysis of cell culture supernatants 
 
2.2.3.1 Clinical laboratory analysis  
Supernatant analysis was performed at the Department of Clinical Chemistry and 
Laboratory Medicine (University Hospital of Regensburg, Germany) using the Advia 
1800 analyzer (Siemens Healthcare Diagnostics, Eschborn, Germany). To determine 
cytotoxic effects of FFA, cells were seeded in 6 well plates (Corning, New York, USA) 
and grown overnight followed by stimulation with different concentrations of oleate for 
48 hours. Subsequently, supernatants were collected and centrifuged at 20,000 g for 5 
minutes in order to remove debris and transferred in new cups for measurement. As a 
marker for cell viability, the amount of lactate dehydrogenase (LDH) is commonly used 
and therefore was determined in laboratory analysis, here.  
 
2.2.3.2 Cytotoxicity Detection Kit 
Plus
 
Lactate dehydrogenase (LDH), a cytoplasmatic enzyme that is present in all cells, is 
rapidly released into the cell-culture supernatant upon damage of the plasma membrane. 
It is a fairly stable enzyme which is widely used to evaluate the presence of toxicity of 
tissue and cells. In the Cytotoxicity Detection Kit PLUS (LDH) (Roche Diagnostics, 
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Mannheim, Germany) LDH activity is determined by a coupled enzymatic reaction, 
whereby the tetrazolium salt INT (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl 
tetrazolium) is reduced to formazan. An increase in the amount of dead or plasma- 
membrane-damaged cells results in an elevated level of LDH enzyme activity in the 
culture supernatant. This increase in the supernatant directly correlates to the amount of 
formazan formed during a limited period of time. The formazan dye formed is water 
soluble and thus can be read with spectrophotometer. 
All supernatants to be examined were centrifuged (2,000 rpm, 5 minutes) for this assay. 
For an amount of one hundred tests, a working solution was mixed by adding 250 µl 
Catalyst (Diaphorase/NAD+ mixture) solved in H2O to 11.25 ml dye solution 
(iodotetrazolium chloride and sodium lactate). A volume of 100 µl of each sample was 
diluted 1:5 with PBS buffer. A mixture of each 100 µl/well working solution and 
diluted sample were incubated for approximately 30 minutes at room temperature in the 
dark. After the reaction, the assay was terminated by adding 50 µl stop solution per 
well. The dye formed was read with EMax® Microplate Reader (MWG Biotech, 
Ebersberg, Germany) at a wavelength of 490 nm and a reference absorbance 
wavelength of 650 nm. 
 
 
2.2.4 Statistical analysis  
 
Values are presented as mean ± SEM or ± SD as indicated. Comparisons between 
groups were made using the Student’s unpaired t-test or when appropriate, ordinary 
one-way ANOVA test. A p value < 0.05 was considered statistically significant and 
p < 0.01 highly significant. All calculations were performed using the statistical 
computer package GraphPad Prism version 6.00 for Windows (GraphPad Software, San 
Diego, USA). 
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3. Results 
 
Free fatty acids (FFA) play an important role in conjunction with hepatocellular 
carcinoma (HCC) or its pathogenesis, respectively. However, in terms of the effects of 
proliferation and migration in patients already having developed a HCC, no data is 
available at present. The aim of the thesis was to address this issue. In particular, the 
focus was placed on the following four aspects: 
 
3.1 Effects of free fatty acids on cytotoxicity of HCC cells 
3.2 Effects of free fatty acids on lipid accumulation in HCC cells 
3.3 Effects of free fatty acids on proliferation of HCC cells. 
3.4 Effects of free fatty acids on migration of HCC cells 
3.5 Effects of glucose in culture medium on HCC cells. 
 
 
3.1 Effects of free fatty acids on cytotoxicity of HCC cells 
 
First, HCC cells were stimulated with different doses of oleate to reveal the cytotoxic 
range. Chronic exposure to elevated levels of FFA causes cell death in hepatocytes as it 
was shown for non-alcoholic steatohepatitis (NASH). The toxicity of saturated FFA 
such as palmitate thereby is much greater to human hepatoma cells (Hep G2) than 
unsaturated ones (Srivastava and Chan, 2008). Oleate is an unsaturated FFA commonly 
used in HCC research being an appropriate fatty acid for a gentle stimulation of HCC 
cells. Thus, oleate exemplarily was used in this thesis for all experimental trials.  
 
 
3.1.1 Effects of oleate treatment on HCC lactate leakage 
 
Srivastava et al. already revealed that based on measurements of lactate dehydrogenase 
(LDH) as a well-established marker for cytotoxicity, there is no significant release of 
LDH detectable in Hep G2 cells, which were exposed to oleate at an elevated 
physiological concentration of 0.7 mM (Srivastava and Chan, 2007). Our analysis of 
supernatants in the Department of Clinical Chemistry and Laboratory Medicine showed 
no explicit difference between the cells having been stimulated with concentrations up 
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to 0.6 mM oleate and control cells, which were incubated with DMEM (1% FCS) for 48 
hours (Figure 3.1). No cytotoxicity could be found for the tested dose range. Results 
could be confirmed by using the Cytotoxicity Detection Kit Plus from Roche (Roche 
Diagnostics, Mannheim, Germany) (Figure 3.2). The experimental trial was conducted 
with all four cell lines of this study, that is to say Hep G2, Hep 3B, HUH7 and PLC. 
Figures 3.1 and 3.2 exemplarily show the results for HUH7 cells.    
 
 
 
Figure 3.1 LDH leakage for the detection of cytotoxicity in HUH7 cells treated with different doses 
of oleate. ol oleate, ctr control. The amount of lactate dehydrogenase (LDH) was measured 48 h after 
stimulation. Analysis was performed by the Departement of Clinical Chemistry and Laboratory Medicine 
(University Hospital of Regensburg, Germany). 
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Figure 3.2 LDH leakage for the detection of cytotoxicity in HUH7 cells treated with different doses 
of oleate. ol oleate, ctr control. The amount of lactate dehydrogenase (LDH) was measured 48 h after 
stimulation. For analysis, Cytotoxicity Detection Kit Plus from Roche was used. 
 
 
 
3.1.2 Effects of oleate treatment on cellular morphology 
 
Whilst supernatants were collected for technical analysis, cells were photographed for 
documentation of macroscopically visible effects of stimulation with oleate. HUH7 cells 
cultivated in medium with oleate 0.2 mM, 0.3 mM and 0.6 mM, respectively, visually 
showed no signs of cytotoxicity compared to control cells. However, multiple tiny 
globules of fat accumulated, which could be seen as the morphological correlate for 
lipid uptake by HCC cells. Additionally, the cell layer increasingly condensed dose-
dependently. More precisely, high concentrations of oleate such as 0.6 mM were 
difficult to be evaluated with regards to toxicity due to the conglomeratic growth of 
cells. This phenomenon considerably appeared for the highest oleate concentration, 
which was 0.6 mM. A link between increasing oleate concentration and visibly 
detectable lipid accumulation could be drawn, as well (Figure 3.3). 
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IV  
Figure 3.3 HUH7 cells stimulated with oleate 0.2 mM, 0.3 mM, 0.6 mM, respectively (magnification 
40x). Ol oleate, ctr control. Lipid droplets accumulate considerably with increasing concentrations of 
oleate. No cytotoxicity visibly detectable.  
 
 
 
3.2 Effects of free fatty acids on lipid accumulation in HCC 
cells 
 
The next step in this study was to investigate the role of FFA with regards to 
intracellular lipid accumulation. Therefore, a smaller dose range was chosen to ensure 
nontoxic concentrations. Liver is the key organ for metabolism of free fatty acids (FFA) 
(Cowen et al., 1977) and FFA are the initial point of triglyceride synthesis in liver tissue 
(Donnelly et al., 2005). Animal model trials have shown an increased level of FFA in 
plasma of tumor bearing animals (Frederick et al., 1956). Tumor cells are believed to 
use elevated amounts of FFA as metabolic substrates (Spector et al., 1967).  Eventually, 
excess supply drawn from mobilization of fat tissue is utilized as a fuel source in 
hypermetabolic cancer patients (Legaspi et al., 1987). Cells were examined by 
focussing on FFA (chapter 3.2.1) and triglycerides (TG) (chapter 3.2.2) uptake. The 
uptake in the intracellular compartment represents an inalienable condition concerning 
further metabolic transformations of the FFA.  
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3.2.1 Accumulation of free fatty acids 
 
HCC cells were stimulated with oleate (0.1 mM, 0.2 mM and 0.3 mM) for 48 hours. 
Cells were harvested and the obtained cell pellet was examined with FFA quantification 
assay from Roche (see chapter 2.2.1.5). The amount of FFA was significantly higher in 
cell pellets that were cultivated in medium with oleate compared to control. 
Furthermore, the levels of FFA increased with the concentration of oleate in the culture 
medium. To represent the effects proved for all four cell lines, results for Hep 3B cells 
are displayed here (Figure 3.4) exemplarily. 
 
Figure 3.4 Amount of FFA measured in cell pellets of Hep 3B compared to control cells. 
Measurement was performed after stimulation for 48h with indicated oleate concentrations. FFA Free 
fatty acids, ol oleate, ctr control. Values are displayed as mean ± SEM; * p < 0.05 compared to control. 
 
 
3.2.2 Accumulation of triglycerides  
 
FFA appear in their free form, but are also esterificated to glycerine in the intracellular 
compartment yielding triglycerides. The level of FFA was measured in cells grown with 
the same experimental conditions as described in chapter 3.2.1. For analysis, 
Triglyceride quantification assay from Roche (see chapter 2.2.1.6) was used. The results 
were similar to the findings for FFA (see chapter 3.2.1). Compared to control, the 
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triglyceride level was significantly elevated in cell pellets that were cultivated in 
medium with oleate in the first place (Figure 3.5). Comparably to our results detected 
for FFA in chapter 3.2.1, the levels of triglycerides increased proportionally with the 
concentration of oleate in the culture medium applied on cells before investigation.  
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Figure 3.5 Accumulation of Triglycerides in four HCC cell lines treated with different doses of 
oleate for 48 h. ol oleate, ctr control, TG triglycerides. For analysis, cells pellets were used. TG 
triglycerides. Values are displayed as mean ± SEM; * p < 0.05 compared to control. 
 
 
Significantly elevated intracellular concentrations of both, FFA and triglycerides could 
be detected. In addition to this finding, a dose-dependent conduct was striking. 
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3.2.3 Oil Red O Staining 
 
Cell analysis with regards to pathways of FFA being present in the culture medium of 
HCC cells revealed uptake of FFA. The discovered storage in form of triglycerides 
could be seen as initial step for further metabolic processes. These findings conjured up 
the question whether the lipid accumulation could actually be detected visually, as well. 
In chapter 3.1.2, photographs taken of cells that were stimulated with oleate provided an 
indication for lipid uptake in form of intracellular lipid droplets. The aim now was to 
highlight these lipid droplets with a special staining. Oil Red O Staining technique was 
used following the protocol described in chapter 2.2.1.7. Cells optically clearly showed 
lipid accumulation in general as well as dose dependence. The latter could be visualized 
by the both macroscopically and microscopically detectable growing intensity of Oil 
Red dye intensifying with the applied concentration of oleate (Figure 3.6).   
 
 
 
Figure 3.6 Oil Red O Staining of PLC (A) and HUH 7 (B) cells 48 hours after adding the indicated 
stimulants (magnification 40x). Ol oleate. The red dye tints fat in general after a fixation process of the 
cells. Red staining and thus lipid accumulation increases with concentration of oleate. 
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3.3 Effects of free fatty acids on proliferation of HCC cells 
 
A recent review published by Duan et al. in 2012 emphasizes the significance of 
nonalcoholic fatty liver disease (NAFLD) of being a risk factor for contracting 
hepatocellular carcinoma. NAFLD is the hepatic manifestation of the metabolic 
syndrome, which is characterized by various abnormalities such as insulin resistance, 
obesity, hypertension, but also hyperlipidemia (Siegel et al., 2009). Thus, the conclusion 
could be drawn that the metabolic syndrome including elevated plasma levels of free 
fatty acids plays a key role in the development of HCC. Its relevance for tumor progress 
is probable. Consequently, the proliferation of HCC cells was investigated while 
creating an environment similar to conditions being present in hyperlipidemia. Two 
assays with different techniques were used for examining proliferation. XTT – 
proliferation assay profits of a chemical reaction where a dye is formed that can be 
measured colorimetrically (see chapter 2.2.2.1). The xCELLigence System from Roche 
(see chapter 2.2.2.2) by contrast, quantifies proliferation by means of electric 
impedance.  
 
 
3.3.1 Measurement of proliferation by XTT proliferation 
assay  
 
For investigation of proliferation, cells were preincubated with a definite range of oleate 
concentrations. Experimental trials were conducted equally in terms of time period, 
concentrations and cell density. Stimulation of HCC cells with oleate concentrations of 
0.1 mM and 0.2 mM showed no effect on proliferation activity compared to control and 
cells being stimulated with BSA of equal concentration, respectively (Figure 3.7). 
Oleate 0.3 mM appeared to have a rather negative impact on proliferation, as values lag 
behind control. The sharp bend which can be noticed in several graphs at the beginning 
of the assay (e.g. at 0.5 days in Figure 3.7) is a known phenomenon for this method. A 
possible reason is that cells are likely to react very sensitive, when a new medium with 
stimulants is applied and therefore initially tend to lower proliferation rates.  
Results 
 35 
 
Figure 3.7 XTT activity of Hep G2 cells treated with oleate, BSA or unstimulted control cells. ol 
oleate,  ctr control Cells were preincubated with indicated concentrations of oleate and BSA. Extinctions 
measured 3h after adding XTT to cells are depicted. Values are displayed as mean ± SEM. 
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Interestingly, BSA showed a slightly higher proliferation rate compared to cells treated  
with oleate and control cells, respectively (Figure 3.8).  
 
 
Figure 3.8 XTT activity of Hep G2 cells stimulated with different doses of BSA. ctr control. Values 
are displayed as mean ± SEM. 
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Similar findings were uncovered for HUH 7 cells (Figure 3.9). No significant change of 
proliferation rate could be obtained for stimulation with oleate.  
 
Figure 3.9 XTT activity of HUH7 cells treated with oleate, BSA or unstimulted control cells. ol 
oleate,  ctr control Cells were preincubated with indicated concentrations of oleate and BSA. Extinctions 
measured 3h after adding XTT to cells are depicted. Values are displayed as mean ± SEM. 
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The impact of BSA on proliferation (see Figure 3.8) was also confirmed for HUH 7 
cells, (Figure 3.10) to an even more obvious extend as revealed for HepG2.  
 
 
Figure 3.10 XTT activity of HUH7 cells stimulated with different doses of BSA. ctr control. Values 
are displayed as mean ± SEM. 
 
 
 
3.3.2 Measurement of proliferation by xCELLigence System  
 
Another approach to identify cell viability and proliferation is xCELLigence system 
from Roche (Roche Diagnostics, Mannheim, Germany, see chapter 2.2.2.2). In contrast 
to XTT assay, which metabolically forms a dye, the xCELLigence system makes use of 
impedance as a marker for proliferation. The differences as well as advantages of each 
method are highlighted in chapter 2.2.2.1 and 2.2.2.2. Thus, this method completed the 
investigations of proliferation by taking a completely different approach. For 
concentrations of 0.1 mM and 0.2 mM, no significant changes in proliferation rates 
were detected for all cell lines except for HUH 7. At a concentration of 0.2 mM, 
proliferation of cells was significantly higher all along the time slot with BSA, when 
compared to oleate (Figure 3.11) 
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Figure 3.11 Proliferation of HUH7 cells stimulated with oleate 0.2 mM and BSA 0.2 mM. 
xCELLigence system was used as measurement tool. Red = oleate, green = BSA; blue = control (= BSA 
0.1). Values are presented as means ± SD. * p < 0.05 oleate compared to BSA, ** p < 0.01 oleate 
compared to BSA. 
 
Comparing proliferation rates obtained for 0.3 mM between the cell lines, several 
aspects were striking. Figure 3.12 depicts the results obtained for Hep G2, Hep 3B and 
PLC cells at a concentration of 0.3 mM. For all cell lines, oleate exhibited an inhibitory 
effect. Compared to control, the proliferation rate of oleate-treated Hep 3B cells was 
significantly lower at 0.5 days (36 hours). For Hep G2 cells, it was significantly lower 
at 0.5 days (36 hours) and 1.0 days (48 hours), respectively. PLC cells had a 
significantly lower proliferation rate for oleate 0.3 mM compared to BSA and control 
all along the time slot (Figure 3.12). Comparing BSA to control, only Hep 3B cells 
showed a significant increase in proliferation rate at 0.5 days (37 hours) and 1.0 days 
(48 hours) and a significant increase at 2.0 days (72 hours) and 2.8 days (96 hours).  
As results obtained for XTT-assay (see chapter 3.3.2) gave hints that BSA itself might 
play a role, BSA treatment in comparison to oleate was investigated. Results for HUH7 
cells depicted in Figure 3.11 already showed a distinct difference between BSA 0.2 
mM and oleate 0.2 mM for the benefit of BSA. This phenomenon occurred for the other 
cell lines as well, however initially at a concentration of 0.3 mM. All cell lines showed 
significantly higher proliferation rates when stimulated with BSA than with oleate 
(Figure 3.12). The proliferation rate of Hep 3B and PLC cells in BSA was significantly 
elevated compared to oleate treated cells, all along the analyzed time slot. For Hep G2 
cells, a significant elevation was revealed at 0.5 days (36 hours) and 1.0 days (48 hours) 
after adding stimulants whereas after 2.0 days (72 hours) and 3.0 days (96 hours), 
proliferation was significantly higher. To conclude, Hep G2, Hep 3B and PLC cells 
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showed significantly higher proliferation rates for BSA compared to oleate. This 
surprising aspect was already shown applying XTT-assay (see chapter 3.3.1).    
 
 
 
Figure 3.12 Proliferation rates of Hep G2, 3B and PLC cells stimulated with oleate 0.3 mM and 
BSA 0.3 mM. xCELLigence system was used as measurement tool. Red = oleate, green = BSA; blue = 
control (= BSA 0.1). Values are presented as means ± SD. + p < 0.05 for BSA compared to control, ++ p 
< 0.01 for BSA compared to control, +++ p < 0.001 for BSA compared to control; # p < 0.05 for oleate 
compared to control, ## p < 0.01 for oleate compared to control, ### p < 0.001 for oleate compared to 
control; * p < 0.05 for  oleate compared to BSA, ** p < 0.01 for oleate compared to BSA , *** p < 0.001 
for oleate compared to BSA 
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Finally, oleate and BSA concentrations of each cell line were compared among each 
other. Surprisingly, all cells reacted similar. A dose-dependent induction of proliferation 
in BSA-treated cells was described in chapter 3.3.1, and could be confirmed here. A 
reciprocal effect was found for oleate. More precisely, a decrement in cell proliferation 
was noticeable for oleate. Thus, not only a difference between oleate and BSA was 
revealed, but also a dose dependent change in proliferation for both, oleate and BSA. 
Figure 3.13 exemplarily depicts the results found for HUH 7 cells. 
 
 
Figure 3.13 Proliferation of HUH 7 cells stimulated with oleate and BSA. xCELLigence system was 
used as measurement tool. Red =  0.3 mM,  green =  0.2 mM; blue = 0.1 mM. Values are presented as 
means ± SD. 
 
In summary, investigation of proliferation showed various effects depending on 
different stimulants, especially for a concentration of 0.3 mM, several distinctive 
features could be revealed. Amongst others, oleate seemed to have a negative effect on 
proliferation, whereas BSA dose-dependently elevated proliferation rates especially 
when using xCELLigence system as measurement tool but also with XTT proliferation 
assay (see chapter 3.3.1).  
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3.4 Effects of free fatty acids on migration of HCC cells  
 
Tumor cells in general are characterised by several changes in metabolism. Apart from 
an increase in proliferation, the capacity to form metastases is an important feature, too. 
Metastasis is the most frequent cause of death for patients with cancer (Yamaguchi et 
al., 2005). Tumor cell migration is one step in the process of forming metastases. 
Therefore, it is important to know how changes in the microenvironment trigger tumor 
cells to invade tissue. Conceptually, there are two forms of cell migration to be 
distinguished. The first is directional cell migration with intrinsic cell directionality and 
external regulation. On the other hand, there is random cell migration, which occurs 
when a cell possesses relatively low intrinsic directionality (Petrie et al., 2009). 
Consequently, the next step of this study was to investigate the migratory potential of 
HCC cells with FFA in the culture medium being present. The aim was to create a 
microenvironment similar to the one in patients suffering from the metabolic syndrome. 
Directional cell migration was simulated by providing a culture medium with 20% FCS 
in the lower compartment of the migration plate, whereas for random migration 0% 
FCS was used (see chapter 2.2.2.3).  
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3.4.1 Effect of free fatty acids on the migratory potential of 
HCC cells  
 
Migration assay from Cultrex (Trevigen, Gaithersburg, USA) was used to analyze the 
migration of HCC cell lines (see chapter 2.2.2.3). For this assay, cells were incubated 
for 24 hours with stimulants before migration assay was applied. Results for PLC cells 
are presented exemplarily, here. In random cell migration, no significant change of the 
migratory potential was observed for both stimulants, oleate and BSA compared to 
control (Figure 3.14).  
 
Figure 3.14 Random cell migration of PLC cells stimulated with oleate and BSA. ctr control, ol 
oleate. No significant difference between oleate, BSA and control detectable. Values are presented as 
means ± SD. 
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Next, directional cell migration was analyzed. Similar to the findings for random cell 
migration, both BSA and oleate exhibited no significant effects on migration of PLC 
cells (Figure 3.15). 
 
 
Figure 3.15 Directional cell migration of PLC cells stimulated with oleate and BSA. ctr control, ol 
oleate. No significant difference between oleate, BSA and control detectable. Values are presented as 
means ± SD.  
 
 
To sum up, no significant change in the migratory potential was observed for both, 
oleate and BSA neither for random, nor for directional migration.  
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3.5 Effect of glucose in culture medium on HCC cell lines 
 
In chapter 1.2 the link between high levels of FFA and high glucose levels was already 
described with regards to the metabolic syndrome. Analysis of the effect of FFA on 
HCC cell proliferation and migration was the main aspect of this thesis. Due to the 
surprising and unexpected facts revealed concerning the effect of BSA on proliferation, 
further investigations followed. Previous experimental trials were conducted exclusively 
with high glucose medium, which contains a glucose concentration of 4.5 g/l. This 
medium was used in order to examine the role of high glucose levels in the culture 
medium and thus getting a distinctive insight into the complex constellations of patients 
with metabolic syndrome. Hence, the influence of the glucose level was explored by 
introducing a low glucose medium now for supplementary experimental trials with a 
glucose concentration of 1.0 g/l.  
 
 
3.5.1 Measurement of proliferation by XTT Proliferation 
assay 
 
The effect of low glucose itself was investigated in this trial. Therefore, the comparison 
of different cell numbers between low and high glucose was made. As expected, high 
glucose had a positive effect on proliferation (Figure 3.16). 
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Figure 3.16 Proliferation of HUH7 cells in low glucose and high glucose medium. Comparison of 
normal, half and double amounts of cells. ZZ x ½ = half amount of cells; ZZ x 1 = standard amount of 
cells ; ZZ x 2 = double amount of cells. Values are presented as means ± SEM. 
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4. Discussion 
 
Elevations of plasma levels of free fatty acids (FFA) play an important role in the 
development of many liver-related diseases (Felber et al., 2002). The metabolic 
syndrome, for instance is a severe constellation of symptoms that comprises several 
problems which are directly or indirectly linked to a change in metabolism of FFA. 
Obesity, hyperlipidemia, diabetes, insulin resistance and hypertension are its main 
characteristics (Farrell et al., 2006; Siegel et al., 2009). The hepatic manifestation of the 
metabolic syndrome is nonalcoholic fatty liver disease (NAFLD), which subsumes 
several liver diseases that are not related to toxic alcohol intake. NAFLD ranges from 
benign fatty liver to non-alcoholic steatohepatitis (NASH) (Siegel et al., 2009; Duvnjak 
et al., 2009) and has turned out to be associated with hepatocellular carcinoma (HCC) as 
fatal last step in a row of morphological and functional liver changes (Duvnjak et al., 
2009). Whereas the exact pathophysiological pathway behind the progress from NASH 
to HCC remains rather opaquely, the relation of NASH to insulin resistance and 
subsequent inflammatory cascade likely contribute to the carcinogenic potential (Starley 
et al., 2010). It is also known that adipose tissue induces expression of leptin, which in 
turn, promotes the progression from NASH to HCC in animal models (Ilejima et al., 
2002). Leptin itself up-regulates the signal transduction pathway involved in cancer 
progression, such as the Janus kinase/signal transducer and activator of transcription 
pathway, the protein kinase B pathway and the extracellular signal-regulated kinase 
pathway in HCC cells (Saxena et al., 2007). These findings support the theory of the 
link between changes in lipid metabolism and the tumorigenic process beginning with 
hepatic steatosis with a gradual progression to HCC as end point against the background 
of obesity and its associated diseases. Consequently, the question is conjured up, how 
these changes in metabolism affect further development of arisen HCC. The emphasis 
of this thesis was put on the condition of prevalent elevated levels of FFA, that is to say 
in particular unsaturated oleate. However, no data concerning the impact of 
hyperlipidemia on HCC cells is available at present. Therefore, the aim of this thesis 
was to address this issue. In particular, cytotoxicity (see chapter 3.1), intracellular lipid 
accumulation (see chapter 3.2), proliferation (see chapter 3.3), and migration of four 
HCC cell lines were analyzed. To come full circle, additional experimental trials with 
low glucose medium were conducted as an outlook (see chapter 3.5). Thus, an insight 
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into the role of the high glucose plasma levels in the microenvironment, which itself are 
another aspect of the metabolic syndrome is delivered. 
In the present study, the first aim was to test the cytotoxicity of FFA on HCC cells. 
Evidence was already shown for the toxicity of saturated fatty acids such as palmitate 
on Hep G2 cells in previous studies (Li et al., 2008). It was found that palmitate induces 
significantly higher toxicity as compared to the control, oleate, and linolate cultures 
(Riss et al., 2004). Experimental trials with Hep G2 and HUH 7 hepatoma cell lines 
revealed signs of lipotoxicity after stimulation with palmitate at concentrations higher 
than 0.2 mM (Malhi et al., 2006). However, when stimulated with oleate 0.7 mM, no 
significant elevation of lactate dehydrogenase (LDH) release compared to control group 
was detectable (Li et al., 2008). LDH release as a marker for cytotoxicity is a well-
established method. It is a cytosolic enzyme that leaks out into the medium when the 
cell membrane is compromised, such as when exposed to toxic chemicals (Riss et al., 
2004). In this study, the findings by Li et al. (2008) could be confirmed. Neither 
measurement of supernatants conducted with Cytotoxicity Detection Kit PLUS (LDH) 
from Roche (Roche Diagnostics, Mannheim, Germany) nor analysis in the Department 
of Clinical Chemistry and Laboratory Medicine (University Hospital of Regensburg) 
featured a significant elevation of LDH leakage compared to control. Thus, no 
cytotoxicity could be detected for the chosen range of oleate concentrations ranging 
from 0.05 mM to 0.7 mM. 
Liver is the key organ for lipid metabolism. In particular, FFA play a major role, as they 
are the source for triglyceride synthesis (Cowen et al., 1977; Donnelly et al., 2005). 
Triglycerides in turn are further metabolized to different forms of lipoproteins 
(Bradbury et al., 2006). Many different studies provided evidence that obesity and 
insulin resistance, which are co-existing features of the metabolic syndrome, are 
associated with impaired free fatty acid metabolism (Boden, 2008). The elevated levels 
of FFA increase accumulation of triglycerides in liver cells, which commonly is known 
as steatosis (Felber et al., 2002). Its link to NASH and HCC was already described 
previously. Additionally, research data is available proving that tumor metabolism itself 
also is responsible for high levels of FFA. The extracellular pool of FFA in tumor 
bearing patients is mainly drawn from adipose tissue (Mermier and Baker, 1974). The 
notable increased levels of FFA are attributed to the hypermetabolic state in cancers in 
general, where they serve as substrates for tumor cells (Legaspi et al., 1987; Spector et 
al., 1967). For instance, in patients with breast cancer, both levels of saturated and 
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mono-unsaturated fatty acids in plasma are described to be significantly increased 
compared to control (Kumar et al., 1991). A recent article reports excessive release of 
FFA from visceral adipocytes that have several consequences on protein level. For 
instance, it leads to production of inflammatory and proatherogenic proteins by 
activation of NFκB and c-Jun NH2-terminal kinase (JNK) pathways in liver and 
endothelial cells, and promotes NAFLD. CD36 was identified to mediate uptake of FFA 
from circulation and intracellular transport of longchain fatty acids in diverse cell types 
such as hepatocytes (Su et al., 2009). These mechanisms are considered to play 
important roles in tumor cell metabolism as well. An overload of fatty acids leads to 
lipid accumulation in Hep G2 cells according to previous publications (Gómez-Lechón 
et al., 2007). In this study, significantly elevated levels of FFA and TG were found in 
HCC cells cultivated with concentrations ranging from 0.1 mM – 0.3 mM oleate 
compared to control as well as a dose-dependent uptake. These findings prove lipid 
uptake and accumulation by HCC cells when excessive supply of FFA (oleate) was 
provided in the culture medium. Oil red O staining visually confirmed the obtained 
results. Thus, our results are consonant with previous studies reporting the significant 
induction of steatotic triglyceride formation due to high levels of mono-unsaturated 
fatty acids such as oleate (Listenberger et al., 2003; Okere et al., 2006) with all 
successional consequences having already been described.  
In general, dysregulation of proliferation is one of the most important features of human 
cancers including hepatocellular carcinoma (Tsuboi et al., 2004). As respects HCC, 
increase in proliferative activity is correlated with both, the early developmental stage 
and malignant progression of HCC (Sugitani et al., 1998; Matsuno et al., 1990). 
Important signal transduction pathways were revealed for pathogenesis as well as for 
tumor progression. For instance, activation of Ras/Raf/MEK/ERK and 
Ras/PI3K/PTEN/Akt/mTOR signalling pathways were shown over the past 25 years to 
play key roles in the transmission of proliferative signals from membrane bound 
receptors (Steelman et al., 2011). Activation of PI3K/PTEN/Akt/mTOR signalling 
through mutation, inactivation or silencing of pathway components occured in HCC as 
well as in various other malignancies (Calvisi et al., 2007). A recent study demonstrated 
that activation of Ras pathway occurred in 100% of HCC specimen analyzed when 
compared with normal liver tissue (Calvisi, 2006). A finding that matches these 
observations is that expression of the Ras inhibitors Sprouty-related protein with 
Ena/vasodilator-stimulated phosphoprotein homology-1 domain (Spred-1) and Spred-2 
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proteins in human HCC tissues frequently were decreased. Its link to obesity- related 
HCC was drawn by a study of Saxena et al. (2007), which for the first time 
demonstrated that leptin promotes growth and invasiveness of HCC due to activation of 
Ras/Raf/MEK/ERK signalling. Leptin itself is a key molecule involved in the regulation 
of body weight. Additionally, over a decade ago, an important role for Wnt/β-catenin 
signalling in HCC was discovered (de La Coste, 1998). It becomes apparent that this list 
could be continued almost arbitrarily long and the interplay of various genes that serve 
to regulate tumor growth and tumor suppression are rather complex and interweaved. In 
contrast to recent data, this study aimed to leave protein expression level in order to get 
hints, to what extend FFA offered in the culture medium exihibit proliferative effects on 
HCC cells. Thus, a microenvironment very similar to the one in humans with metabolic 
syndrome was created with experimental settings imitating the environment in human 
beings. As previously described, well-established, classic XTT proliferation assay and 
the novel impedance-based xCELLigence system were juxtaposed. With classic XTT 
proliferation assay, no significant change in proliferative activity for oleate 
concentrations of 0.1 mM and 0.2 mM could be detected. However, oleate 0.3 mM 
tends to have an inhibitory effect on cell growth. Similarily, xCELLigence system 
showed no significant changes for the proliferation with oleate concentrations of 0.1 
mM and 0.2 mM, when compared to control. HUH7 cells had a significantly better 
proliferation with 0.2 mM BSA than compared to 0.2 mM oleate and control however, 
which then again gave hints for an important role of BSA. At an oleate concentration of 
0.3 mM, all cell lines had significantly decreased proliferation rates compared to control 
and to accordant BSA concentrations. The positive effect of BSA previously detected in 
XTT proliferation assay could be confirmed for all cell lines as well, especially for Hep 
3B, where a significant difference was remarkable. Ascending concentrations of oleate 
exhibit a dose-dependent negative effect on proliferation. On the contrary, BSA dose-
dependently seems to be a good stimulant for HCC cell lines for growth. 
In summary, three main aspects are striking: First, one might assume that FFA at high 
plasma levels stimulate HCC development as they promote development from simple 
liver disease to HCC, as well (Mermier and Baker, 1974; Siegel et al., 2009). Hence, 
oleate in high levels does not conduce to tumor proliferation, but even has an inhibitory 
effect. Second, a dose-dependency for both, oleate and BSA, could be detected.  
Lastly, the most surprising finding yet is the positive effect of BSA. There is no data 
available about the effect of BSA on proliferation of tumor cells, at present. As 
Discussion 
 51 
experimental results in this study repeatedly gave hints that BSA itself exhibits a 
positive effect on proliferation, we took a closer look at its impact on HCC cells.  A 
possible explanation for the surprising effects of BSA on proliferation could be the 
special features of BSA molecules. In particular, one important function of serum 
albumin is to bind long-chain fatty acids and thereby make them more soluble in 
aqueous solutions. This fact is of physiological significance, as albumin binds almost all 
of the FFA that are released into the blood from adipose cells (Spector et al., 1969). 
However, it also has relevance with regards to interpretation of experimental trials 
conducted with BSA and FFA, in particular. Spector et al. already assumed six high-
energy binding sites for long-chain FFA amongst a large number of weaker binding 
sites (Spector et al., 1969). As FFA are complexed in albumin, BSA consequentially is 
carried along as control in this study. This turned out to be very important as a new 
aspect, as namely the unique effect of BSA could be revealed. With regards to results, 
one might speculate different possible explanations for this effect. For instance, BSA 
itself could truly have an impact on proliferation that was not revealed so far. Another 
reason could be an increase in proliferation rate that is exclusively conducted by the 
FFA-BSA complex. More precisely, the increase in proliferation rate exclusively is 
exhibited when both FFA and BSA are present in the culture medium. However, this 
condition then reversely does not eliminate the theory of any positive effects of FFA. 
Further investigations with this topic seem to be adequate and necessary. Especially 
experimental trials conducted with FFA-free BSA added to culture medium might be a 
constructive approach to this topic as a next logical step.  
Another side-effect that shall not be underestimated is the influence of the applied 
measurement method. A recent study compared the xCELLigence system to other 
measurement methods that base on different technologies and are considered as gold 
standard in their field, respectively. The results suggested that xCELLigence RTCA 
technology represents an adequate method to investigate non-invasively cell viability. In 
this field, it has a strong correlation with conventional methods (Limame et al., 2012). 
With regards to the present study, both systems showed similar results, yet with small 
deviances. Results obtained by means of XTT proliferation assay already showed the 
tendency that oleate has an inhibitory effect and BSA a rather stimulating one, though 
xCELLigence system provided a more detailed depiction. Possible reasons might be the 
high number and small intervals of measurements. The advantage of this method was 
that cells were not irritated by taking plates out of the incubator or other manipulations. 
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Another difference influencing test results is the fact that XTT proliferation assay 
measures mitochondrial activity (see chapter 2.2.2.1), whereas xCELLigence bases on 
impedance (see chapter 2.2.2.2). It certainly needs to be clarified in future studies which 
method provides the more suitable indicator for cell proliferation.   
 
The second main topic of this study was to analyze the impact of FFA on migration. In 
general, cancer progression is a complex process with a multitude of single steps. One 
major aspect of progression is the capability of tumor cells to migrate to points rather 
far from a given primary tumor mass which leads to metastasis (Yamaguchi et al., 
2005). In this complex process, infiltration of blood vessels at the primary tumor site 
causes the formation of metastatic lesions in distant organs in the long term (Pantel et 
al., 2008). This vascular invasion is one of the most significant features of HCC, which 
is believed to contribute to intrahepatic and extrahepatic metastasis. Extrahepatic 
metastases of HCC are frequently observed in distant organs such as the lungs, regional 
lymph nodes, kidneys and bone marrow (Chang et al., 2006). Various studies 
investigated the migratory potential of HCC cell lines. For instance, Saxena et al. 
revealed that leptin, a key molecule in the regulation of body weight, not only has 
relevance for proliferation, but also for invasiveness and migration. The connection to 
JAK/STAT pathway as a critical mediator of leptin action was drawn as well (Saxena et 
al., 2007). Another recent study showed that androgen receptor (AR) enhances HCC 
cell migration and invasion which could be blocked by androgen antagonist casodex 
(Ao et al., 2012). Additionally, our group recently found out that zinc finger protein 267 
is up-regulated in HCC and promotes tumor cell proliferation and migration (Schnabl et 
al., 2011). To sum up present research data, various specific scientific investigations 
suggest that HCC migration is a multifaceted topic that still needs to be deciphered in 
detail. This study now aimed to elucidate the impact of FFA on migration as a substep 
of the formation of metastases, as no reference data was available. Both, directional and 
random migration, were analyzed. No significant change to control was to be observed. 
Hence, these results suggest that short-time incubation with FFA does not have any 
effect on migration. However, a link between tumor migration and elevated levels of 
FFA was drawn recently. More precisely, in breast cancer patients it was revealed that 
migration is enhanced by FFA through PAI-1 and SMAD4 (Byon et al., 2009). These 
findings match the observations that FFA mediate an increase of plasminogen inhibitor-
1 (PAI-1) in Hep G2 cells (Chen et al., 2002). One might speculate that possible effects 
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could be revealed when HCC cells are stimulated for a longer period of time. 
Experimental trials of the present work were exclusively conducted with oleate. With 
regards to research data described above, the assumption is conjured up that other FFA 
might be more essential for migration. Further investigations including other FFA as 
well as longer incubation times are likely to provide detailed information about the 
impact of FFA on HCC cell migration and should be applied in future trials.  
The setting of the experimental trials aimed to imitate a microenvironment being 
present at diseases like the metabolic syndrome or NAFLD. The main part of this work 
concentrated on the well-known feature of these syndromes that FFA levels in plasma 
are considerably elevated. However, co-factors which frequently are present in 
association with metabolic diseases are hyperglycemia and diabetes mellitus (DM), 
respectively. They have been identified as a risk factor for developing HCC, as well 
(Lagiou et al., 2000; Fujino et al., 2001). Hence, as future prospects, the use of high 
glucose and low glucose medium without any other additional stimulants, were 
compared to each other. Low glucose exhibited an inhibitory effect on cell proliferation. 
High glucose levels thus can be considered as beneficial for HCC growth. This finding 
is consistent with data shown by a case-control study which excluded other risk factors 
and focussed on the role of diabetes mellitus. Additionally, hyperglycemia plays a key 
role not only in development, but also in progression of HCC (Lagiou et al., 2000). A 
number of reasons might explain the protumorigenic and progressive influence of 
hyperglycemia on HCC cells. For instance, metabolic effects of diabetes mellitus 
increase the risk of HCC through NASH and cryptogenic cirrhosis (Silverman et al., 
1990). Another observation is that functional liver damage is higher among individuals 
suffering from a HCC with diabetes mellitus than among those without a history of this 
disease (Lagiou et al., 2000). To sum up, liver damage that might result from high 
glucose levels due to simple diabetes mellitus, metabolic syndrome or NASH do not 
only increase susceptibility but also facilitate progress of HCC.  
 
Although results seem to be contradictory to correlation of HCC tumorigenicity with 
diseases being characterized by elevated FFA at first glance, a closer look on chronic 
liver disease draws the link. In chronic liver disease, such as NAFLD, albumin plasma 
levels are decreased, whereas FFA levels are elevated (Baršić et al., 2012). As both 
conditions seem to have no accelerating effect for HCC progression, these findings 
indicate that other factors might play a key role. For tumor development it could be 
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demonstrated recently that a lowered level of serum albumin is significantly associated 
with an increased risk for HCC in hepatitis B patients (Lin et al., 2013). This certainly 
proves the theory of an important role of BSA in low concentrations triggering 
transformation of liver tissue to malignant cells. To sum up, the role of albumin or BSA, 
respectively remains opaque. Consequently, the significant effects of BSA still need to 
be established in further investigations to get a better understanding of how HCC 
proliferation and migration are influenced by BSA.    
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6. Abbreviations 
 
BSA bovine serum albumin 
°C degree Celsius 
ctr. control 
dest. destilled 
DMEM Dulbecco’s modified eagle medium 
DNA deoxyribonucleic acid 
et al. et alii 
FFA free fatty acids 
FCS fetal calf serum 
g gram 
g earth’s gravitational acceleration 
h hour 
HbA1c glycosylated hemoglobin 
HBV hepatitis B virus 
HCC hepatocellular carcinoma 
HCV hepatitis C virus 
HDL high density lipoprotein 
HSL hormone-sensitive lipase 
l liter 
LDL low density lipoprotein 
µ mikro- (10-6) 
µg microgram 
µl microliter 
µm micrometer 
m milli- (10-3) 
mg milligram 
min minutes 
ml mililiter 
mM millimolar 
mmol milimol 
NAFLD non-alcoholic fatty liver disease 
NASH  non-alcoholic steatohepatitis 
NFκB nuclear factor kappa B 
nm nanometer 
OD optical density 
Ol oleate 
PBS phosphate buffered saline 
pH pondus hydrogenii 
p-value probability value (statistics) 
RFA radiofrequency ablation 
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rpm rounds per minute 
RT room temperature 
s second 
SD standard deviance 
SEM standard error of the mean 
TACE transarterial chemoembolization 
TG triglyceride(s) 
TNFα tumor necrosis factor α 
VLDL very low density lipoprotein 
WHO world health organization  
XTT 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[phenylamino)carbonyl]-2H-
tetrazolium hydroxide 
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7. Appendix 
 
7.1 Zusammenfassung  
 
Titel: Untersuchung der Einflüsse von freien Fettsäuren auf die Proliferation und Migration 
von in vitro HCC Zellen. 
Einführung: Das Hepatozelluläre Karzinom (HCC) ist der häufigste primäre Leberkrebs 
weltweit. Obwohl laufend neue Therapiemöglichkeiten entwickelt werden, bleibt das HCC 
eine aggressive Krebsart mit oft schlechter Prognose, welche häufig der späten 
Diagnosestellung geschuldet ist. Dabei leidet die Mehrheit der betroffenen Patienten an einer 
chronischen Lebererkrankung wie der Nichtalkoholischen Steatohepatitis (NASH). Diese 
wiederum entwickeln vorrangig adipöse Patienten. Tatsächlich wiegt der Anteil, der durch 
Übergewicht und dessen Folgen entstandenen Hepatozellulären Carcinomata (HCC) 
schwerer, als Hepatitis B (HBV) und Hepatitis C (HCV) Infektionen. NASH bzw. die 
Vorstufen nichtalkoholische Fettlebererkrankung (NAFLD) und Fettleber gehen mit erhöhten 
Blutspiegeln von freien Fettsäuren (FFA) einher. Bei diesen Patienten findet sich in vielen 
Fällen auch das metabolische Syndrom, eine Erkrankung multifaktorieller Genese. Dieses 
Syndrom ist unter anderem durch Hyperglykämie, Insulinresistenz, Hypertonie und 
Adipositas gekennzeichnet und wird in der heutigen Wohlstandsgesellschaft zunehmend zum 
besorgniserregenden Gesundheitsproblem. Die Erhöhung der Plasmaspiegel von freien 
Fettsäuren stellt somit die Schnittstelle von Adipositas, metabolisches Syndrom, NAFLD und 
HCC dar. Des Weiteren sind die abnorm hohen Plasmaspiegel nicht nur für die Entstehung 
eines HCC, sondern auch für den Tumormetabolismus selbst ein wichtiges Charakteristikum.  
Ziel dieser Arbeit war die in vitro Erforschung, inwiefern sich erhöhte Spiegel von freien 
Fettsäuren auf die Proliferation und Migration von HCC Zellen und damit den Tumorprogress 
in Patienten auswirken, bei denen sich bereits ein HCC entwickelt hat.  
Methoden und Ergebnisse: In den Überständen von 4 HCC-Zelllinien, die exemplarisch mit 
Oleat als FFA vorinkubiert wurden, fanden sich keine Hinweise auf Zytotoxizität im 
gewählten Dosisbereich. Diese wurde mittels Bestimmung von Lactat Dehydrogenase (LDH), 
einem etablierten Enzym zur Messung von Zelluntergang, in den Überständen bestimmt. 
Weiterhin ergab die Analyse der Zellpellets eine dosisentsprechende Akkumulation von FFA 
und Triglyzeriden. Diese konnte mittels Oil Red O Färbung auch morphologisch bestätigt 
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werden. Die Untersuchung der Proliferation mit Hilfe von XTT Assays ergab für niedrige 
Konzentrationen von Oleat und BSA keine Auswirkungen auf die Wachstumsraten, für 
höhere einen leicht inhibierenden Effekt. Erstaunlich war, dass mit zunehmender 
Konzentration von BSA, die Proliferationsrate dosisabhängig zunahm. Dieser Effekt konnte 
insbesondere auch durch Verwendung des xCELLigence Systems als Messmethode gezeigt 
werden. Hier fiel zudem auch ein dosisabhängiger Abfall der Proliferationsrate für Oleat als 
Stimulans auf.  
Im zweiten Teil wurde die Auswirkung der FFA auf das Migrationspotential von HCC Zellen 
untersucht. Hier zeigte sich sowohl für die gerichtete, als auch für die ungerichtete Migration 
keine signifikante Änderung im Migrationsverhalten.  
Zuletzt erfolgte als Ausblick die Untersuchung der Proliferation mit einem Medium mit nur 
geringer Glucose Konzentration, um den Einfluss der Glucose einordnen zu können. Im 
direkten Vergleich beider Glucose Medien ohne weiter Zusätze zeigte sich ein positiver 
Effekt durch das Medium mit dem höheren Anteil an Glucose.  
Diskussion: Es zeigte sich, dass Oleat dosisabhängig einen leicht inhibierenden Effekt auf die 
Proliferation von HCC Zellen ausübt. BSA dagegen steigert wiederum dosisabhängig die 
Proliferationsrate. Die Migration von HCC Zellen bleibt durch die Inkubation mit FFA 
unbeeinflusst.   
Diese in-vitro Analysen konnten für Oleat im verwendeten Dosisbereich keine pro-
tumorigene Wirkung auf HCC Zellen nachweisen. Die positiven Korrelationen von hohen 
FFA Spiegeln auf HCC Entstehung und Progression scheint also nicht durch direkte FFA 
Wirkung auf HCC Zellen oder durch andere FFA vermittelt zu werden. 
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